RTNS 2012
Recent articles
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.